September 29, 2009 – Abiomed Inc. announced new clinical data last week at TCT 2009 from Academic Medical Center’s (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II trial, revealing improved left ventricular function, cardiac output and quality of life.
